Is Crizotinib a medically insured drug?

Crizotinib (Crizotinib) is a medical insurance drug and belongs to the scope of Class B medical insurance reimbursement. It is limited to patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer or ROS1-positive advanced non-small cell lung cancer (NSCL). C) Patients are reimbursed. Patients who do not meet the conditions can only purchase the drug at their own expense, and differences in reimbursement ratios in different regions may lead to different reimbursement prices. The price of each box of the original crizotinib drug currently marketed in China may be around RMB 15,000, which is still relatively expensive. For specific information on crizotinib-related medical insurance reimbursement, please consult the local medical insurance bureau or hospital.